NIH starts trial of Pear, Chess apps for opioid use disorderPatient recruitment has begun in a National Institutes of Health (NIH) trial of two digital therapeutics (DTx) for Share XNIH starts trial of Pear, Chess apps for opioid use disorderhttps://pharmaphorum.com/news/nih-starts-trial-of-pear-chess-apps-for-opioid-use-disorder/
DTx company Pear shapes public listing with $1.6bn SPAC mergerDigital health company Pear Therapeutics has foregone the traditional initial public offering (IPO) route to a stock exchange Share XDTx company Pear shapes public listing with $1.6bn SPAC mergerhttps://pharmaphorum.com/news/dtx-company-pear-shapes-public-listing-with-1-6bn-spac-merger/
Ohio is third state to fund Pear’s digital therapeutics to tackle addictionA third US state has agreed to fund Pear Therapeutics’ digital therapeutics (DTx) to treat people with substance Share XOhio is third state to fund Pear’s digital therapeutics to tackle addictionhttps://pharmaphorum.com/news/ohio-is-third-state-to-fund-pears-digital-therapeutics-to-tackle-addiction/
Digital therapies for opioid use disorder need more data, says ICERThere isn’t enough evidence to suggest that digital therapies for people with opioid use disorder (OUD) can improve Share XDigital therapies for opioid use disorder need more data, says ICERhttps://pharmaphorum.com/news/digital-therapies-for-opioid-use-disorder-need-more-data-says-icer/
Pear rolls out digital therapy for schizophrenia under FDA’s COVID-19 schemePear Therapeutics has started a limited launch of its digital therapeutic for people living with schizophrenia under the Share XPear rolls out digital therapy for schizophrenia under FDA’s COVID-19 schemehttps://pharmaphorum.com/news/pear-rolls-out-digital-therapy-for-schizophrenia-under-fdas-covid-19-scheme/
Sandoz says ‘no’ to Pear Therapeutics’ digital apps, handing back rightsNovartis has made no secret of its desire to become a leader in digital therapeutics (DTx), but that Share XSandoz says ‘no’ to Pear Therapeutics’ digital apps, handing back rightshttps://pharmaphorum.com/news/sandoz-says-no-to-pear-therapeutics-digital-app-handing-back-rights/
Expanding the definition of medicineDigital therapeutics are adding new elements to the medical world, but their place in the pharmaceutical sector is Share XExpanding the definition of medicinehttps://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/digital-therapeutics-expanding-the-definition-of-medicine/
FDA clears Pear/Sandoz app for opioid use disorderA second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more Share XFDA clears Pear/Sandoz app for opioid use disorderhttps://pharmaphorum.com/news/fda-clears-pear-sandoz-app-for-opioid-use-disorder/
Novartis and Pear to develop substance use digital therapeuticsNovartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid Share XNovartis and Pear to develop substance use digital therapeuticshttps://pharmaphorum.com/news/novartis-digital-therapeutics-sandoz-pear/
